Abstract: The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
February 13, 2018
Assignee:
The United States of America as represented by the Department of Veterans Affairs
Abstract: Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.
Type:
Grant
Filed:
January 14, 2015
Date of Patent:
January 23, 2018
Assignees:
The Board of Trustees of the University of Arkansas, The United States of America as Represented by the Department of Veterans Affairs
Abstract: Disclosed is a compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: X1-L-X2 wherein L is a linking moiety comprising an enone; and X1 and X2 are each independently an optionally-substituted N-heterocycle. Also disclosed are method for treating pulmonary conditions and other organ or system conditions with the compounds.
Type:
Grant
Filed:
May 9, 2014
Date of Patent:
January 9, 2018
Assignees:
University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as Represented by the Department of Veterans Affairs
Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
Type:
Grant
Filed:
December 23, 2013
Date of Patent:
January 2, 2018
Assignees:
UNIVERSITY OF MIAMI, THE UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Andrew V. Schally, Joshua M. Hare, Norman L. Block, Samirah A. Gomes, Rosemeire M. Kanashiro-Takeuchi
Abstract: Described are surgical drapes and system with universal application to heavy equipment useful in operating room environments. Surgical drape systems of the invention are particularly capable of covering patient support machinery such as hoists, lifts, and slings, whether the equipment is mobile or stationary, or configured as a floor-based or as an overhead support/lifting system. The drapes of the current invention provide for protecting the equipment from exposure to surgical biohazard waste e.g.; blood or body fluids, as well as providing the ability to use equipment that is otherwise not presently allowed to enter into an operating room because of the impossibility to render such equipment sterile. The drapes further allow for the holding, lifting and positioning of the patient whole body or limbs while maintaining sterility during prepping and surgical procedures. Also included are support slings for use with the drapes.
Type:
Grant
Filed:
April 16, 2015
Date of Patent:
January 2, 2018
Assignee:
The United States of America as Represented by the Department of Veterans Affairs
Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.
Type:
Grant
Filed:
December 9, 2014
Date of Patent:
December 26, 2017
Assignees:
University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
Abstract: A method of treating traumatic brain injury (TBI) and other neurological disorders is presented herein. Both conditioned media (CM) containing long non-coding RNAs such as NEAT1 (nuclear enriched abundant transcript 1) and MALAT1 (metastasis associated lung adenocarcinoma transcript 1) as well as human adipose-derived stem cells (hADSCs) themselves (Tx), when administered at least 3 hours post injury, were found to significantly ameliorate motor and cognitive functions in young, but not aged, mice undergoing TBI. Significant reduction in cortical damage and hippocampal cell loss was observed in both Tx and CM groups in young rats, whereas less neuroprotection was detected in the aged rats and mainly in the Tx group but not the CM group, which may in part result from decreased homing of the cells to the spleen.
Type:
Grant
Filed:
January 22, 2015
Date of Patent:
November 21, 2017
Assignees:
University of South Florida, The United States of America as Represented by the Department of Veterans Affairs
Inventors:
Denise R. Cooper, Cesario Borlongan, Paula Cole Bickford, Niketa A. Patel, Lisa Gould
Abstract: Pseudomonas aeruginosa flagellin protein recruits the mammalian host sialidase enzyme neuraminidase-1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC1 (MUC1-ED), thereby exposing a cryptic binding site on the MUC1-ED protein backbone for flagellin binding. NEU1-driven MUC1-ED desialylation rapidly increases P. aeruginosa adhesion to the airway epithelium. MUC1-ED desialylation also increases MUC1-ED cleavage and shedding from the cell surface, where desialylated, shed MUC1-ED competitively blocks P. aeruginosa adhesion to cell-associated MUC1-ED. Presented herein are data showing that exogenously-administered, deglycosylated MUC1-ED peptides reduced adhesion of P. aeruginosa to airway epithelial cells. Also presented are data showing that administration of P. aeruginosa to mice in combination with deglycosylated MUC1-ED decreased P. aeruginosa recovered from the lungs at 48 hr and 72 hr post-infection.
Type:
Application
Filed:
June 22, 2017
Publication date:
November 9, 2017
Applicants:
UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Erik P. LILLEHOJ, Avelino C. VERCELES, Simeon E. GOLDBLUM
Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
Type:
Grant
Filed:
October 25, 2016
Date of Patent:
November 7, 2017
Assignees:
Emory University, The United States of America as represented by the Department of Veterans Affairs
Abstract: The subject invention concerns materials and methods for treating and/or preventing diseases associated with accumulation of A? peptide in neural tissue. The subject invention also concerns materials and methods for treating and/or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and/or treat Alzheimer's disease and Parkinson's disease. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant.
Type:
Grant
Filed:
September 24, 2009
Date of Patent:
October 31, 2017
Assignees:
The United States of America as represented by the Department of Veteran Affairs, University of South Florida
Abstract: Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (PDGF) B, and wherein the multipotent stem cells express a sufficient amount of PDGFB to increase bone mass and strength or bone fracture healing. A lentiviral vector also is disclosed that includes a phosphoglycerate kinase-1 (PGK) promoter operably linked to a nucleic acid encoding PDGFB.
Type:
Grant
Filed:
November 4, 2015
Date of Patent:
October 17, 2017
Assignees:
The United States of America as represented by the Department of Veteran Affairs, Loma Linda University
Inventors:
David Baylink, Kin-Hing William Lau, Wanqiu Chen, Xiao-Bing Zhang
Abstract: The present invention relates to a novel approach means of screening various skin surfaces, including hard to reach areas of the human body, as well as more commonly seen areas such as the foot. The present invention can help patients, especially those who are immobile or those with diabetes self-monitor and transmit the skin condition accurately, so that medical providers may assess the risk or presence of skin tissue breakdown. Thus, provision is made for a remote screening device that can be used in telemedicine or home self-monitoring approaches and offers high resolution image, without artifacts or other distortions that might arise from images taken of feet that have been compressed through standing and the like.
Type:
Grant
Filed:
March 4, 2016
Date of Patent:
October 17, 2017
Assignee:
The United States of America, as represented by Department of Veterans Affairs, Office of General Counsel, Professional Staff Group IV(024)
Inventors:
Gary D. Goldish, Andrew Hansen, Eric Nickel, John E. Ferguson
Abstract: Systems and methods are provided that combine an amplitude modulation SLM with a phase modulating SLM in the same optical illumination system. The combination of the amplitude modulation SLM and the phase modulation SLM allows the optical illumination to compensate for the limitations of amplitude modulation SLM by using phase modulating SLM and conversely to compensate for the limitations of phase modulation SLM by using amplitude modulating SLM.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
October 3, 2017
Assignee:
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Cha-Min Tang, Valentina Emiliani, Peter Pennefather
Abstract: Disclosed are novel methods for preventing or attenuating neuronal damage or stimulating neuronal repair, prior to or following central nervous system injury associated with acute or chronic nervous system injury. Macrophage colony stimulating factor receptor agonists including macrophage colony stimulating factor (M-CSF or CSF-1), interleukin-34 (IL-34), proteins or biologically active fragments thereof, peptides or biologically active fragments thereof, peptidomimetics, or small molecules, and the like are effective for prevention or treatment of acute nervous system injury or chronic nervous system injury involving Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and the like.
Type:
Grant
Filed:
September 9, 2015
Date of Patent:
September 26, 2017
Assignees:
The Board of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Department of Veterans Affairs
Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. is topically applied to the surface of tissues during episodes of graft rejection.
Type:
Grant
Filed:
December 18, 2013
Date of Patent:
September 19, 2017
Assignees:
The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs, The Johns Hopkins University
Inventors:
Mark R. Nicolls, Xinguo Jiang, Geoffrey C. Gurtner, Gregg L. Semenza, Jayakumar Rajadas
Abstract: The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
August 15, 2017
Assignee:
The United States of America as represented by the Department of Veterans Affairs
Inventors:
Robert N. Nishimura, Richard H. Weisbart, James Hansen
Abstract: A system and method of locating a source of a heart rhythm disorder are provided in which a first pair of cardiac signals is processed to define a first coefficient associated with variability of the first pair of signals at a first region of the heart. A second pair of cardiac signals is processed to define a second coefficient associated with variability of the second pair of signals at a second region of the heart. Thereafter, the first coefficient of variability is compared to the second coefficient of variability to determine a direction towards the source of the rhythm disorder.
Type:
Grant
Filed:
October 6, 2014
Date of Patent:
August 8, 2017
Assignees:
The Regents of the University of California, Topera, Inc., The United State of America as represented by the Department of Veterans Affairs
Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for inhibiting an infection with Mtb, preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the inhibition, prevention and/or treatment of tuberculosis are also disclosed.
Type:
Grant
Filed:
October 17, 2016
Date of Patent:
August 1, 2017
Assignees:
Oregon Health & Science University, The United States of America as represented by the Department of Veterans Affairs
Inventors:
David M. Lewinsohn, Deborah A. Lewinsohn
Abstract: System, assembly and method are provided to facilitate reconstruction of cardiac information representing a complex rhythm disorder associated with a patient's heart to indicate a source of the heart rhythm disorder. The complex rhythm disorder can be treated by application of energy to modify the source of the rhythm disorder.
Type:
Grant
Filed:
August 29, 2014
Date of Patent:
August 1, 2017
Assignees:
The Regents of the University of California, Topera, Inc., The United States of America as Represented by the Department of Veterans Affairs
Abstract: The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.
Type:
Grant
Filed:
May 26, 2011
Date of Patent:
July 18, 2017
Assignee:
The United States of America as represented by the Department of Veterans Affairs